AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies

Pammaraju, N., Kantarjian, H., Sweet, K., Wang, E. S., Lane, A. A., Ali, H., Stein, A. S., Yacoub, A., Rizzieri, D., Vasu, S., Gupta, V., Lee, S., Schiller, G. J., Foran, J. M., Taparia, M. S., Rosenblat, T. L., Walter, R. B., Sieminski, D., Anant, M., … Konopleva, M. (2022). AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia, 22, S246–S247. https://doi.org/10.1016/s2152-2650(22)01287-3
Authors:
Naveen Pammaraju
Hagop Kantarjian
Kendra Sweet
Eunice S. Wang
Andrew A. Lane
Haris Ali
Anthony S. Stein
Abdulraheem Yacoub
David Rizzieri
Sumithira Vasu
Vikas Gupta
Sangmin Lee
Gary J. Schiller
James M. Foran
Minakshi S. Taparia
Todd L. Rosenblat
Roland B. Walter
Deborah Sieminski
Madhu Anant
Mrinal M. Patnaik
Tariq I. Mughal
Marina Konopleva
Affiliated Authors:
Todd L. Rosenblat
Author Keywords:
aml
clinical data
myeloid malignancies
phase i/ii
targeted therapy
Publication Type:
Article
Unique ID:
10.1016/S2152-2650(22)01287-3
Publication Date:
Data Source:
Scopus

Record Created: